Onesource Specialty Pharma Limited · NSE:ONESOURCE
Onesource Specialty Pharma — Q1 FY2026 Earnings Presentation
18 slides from Onesource Specialty Pharma's earnings presentation, Aug 4, 2025
Slide 1: Investor Presentation | Q1FY26
Investor Presentation | Q1FY26 August 4th, 2025
Slide 2: Safe Harbor Statement
Safe Harbor Statement Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "i
Slide 3: Quarterly Highlights
Quarterly Highlights
Slide 4: Q1FY26 Performance Snapshot
Q1FY26 results in line with our expectations, steady progress towards GLP-1 commercialisation in H2FY26 ( Q1FY26 Performance Snapshot ) ₹3,273m Revenue Our Q1 performance has been in line with our expectations. During the quarter, we secured 6 new contracts and received $38.2m 12% YoY 25 RFPs across
Slide 5: Q1FY26 financial performance underscores YoY growth across key indicators
Q1FY26 financial performance underscores YoY growth across key indicators In $ m Q1FY26 Q4FY25 Q1FY25 YoY Key Updates Revenue 38.2 49.8 34.2 12% • Revenue: Q1 revenue came in at $ 38.2m / EBITDA 10.3 21.3 7.5 37% ₹ 3,273m, an increase of 12% YoY, primarily driven EBITDA margin (%) 27% 43% 22% ~500 b
Slide 6: Q1FY26 – Business development continues to drive momentum across our diverse offerings
Q1FY26 – Business development continues to drive momentum across our diverse offerings Scaling up DDC capacities 6 New MSAs/licensing • Continuous upward revisions in commercial forecasts for key markets – Canada, Brazil, MENA and India from multiple customers supported by take-or-pay contracts agre
Slide 7: Strengthening operations and increasing capacity while maintaining regulatory excellence
Strengthening operations and increasing capacity while maintaining regulatory excellence Capacity Expansion • Phase 1 DDC capacity expansion ongoing • Phase 2 DDC expansion being accelerated to meet revised customer forecasts • Installing new capabilities in sterile injectables and enhancing lyophil
Slide 8: New Leadership and Board appointments reflect continued efforts to strengthen the organisation
New Leadership and Board appointments reflect continued efforts to strengthen the organisation and enhance independent oversight Board Appointment • Colin Michael Bond joins the Board as Non-Executive Independent Director • Colin is an industry veteran with 15 years of experience as CFO of three pub
Slide 9: Business Outlook
Business Outlook
Slide 10: Reaffirming FY28 organic growth targets: >30% Revenue CAGR, ~40% EBITDA Margins
Reaffirming FY28 organic growth targets: >30% Revenue CAGR, ~40% EBITDA Margins Organic Growth Outlook In $ m FY25 FY28 Q1FY26 Updates • Already committed >50% of ~$100m capex planned for capacity Revenue 171 ~400 expansion, funded through internal accruals, partner commitments, and debt EBITDA 55 ~
Slide 11: Update on potential transaction to acquire two USFDA approved manufacturing sites of Steriscience
Update on potential transaction to acquire two USFDA approved manufacturing sites of Steriscience o The Board of Directors of the Company have appointed a sub-committee of independent directors to evaluate a strategic transaction for the company’s future growth. This sub-committee will evaluate the
Slide 12: Q1FY26 earnings call schedule
Q1FY26 Aug Day: Tuesday 5 Schedule: Date: 5th August 2025 Time: 9:00 AM IST Arun Kumar, Founder & Non-Executive Chairperson Speakers: Neeraj Sharma, CEO & MD Anurag Bhagania, CFO +91 22 6746 8181 Dial In: +91 22 7115 8193 Diamond Pass: Click here for early registration
Slide 13: OneSource at a Glance
OneSource at a Glance
Slide 14: Scaling a first-of-its-kind CDMO platform, distinguished by extensive capabilities and robust financial metrics
Scaling a first-of-its-kind CDMO platform, distinguished by extensive capabilities and robust financial metrics ONE OF ITS KIND CDMO ROBUST MANUFACTURING & PRESENCE ACROSS HIGHLY ATTRACTIVE STRONG AND DEDICATED PLATFORM COMPLIANCE TRACK RECORD MODALITIES INCLUDING GLP-1 FINANCIAL PROFILE MANAGEMENT
Slide 15: One of the widest offerings with industry leading installed capacities and stellar compliance record
One of the widest offerings with industry leading installed capacities and stellar compliance record Drug-device combinations Multi-modal Biologics Soft gelatin capsules1 Sterile Injectables Penicillin fill-finish Integrated Biologics and drug products site development centre Area 450,000 70,000 42,
Slide 16: Strong leadership team with global industry expertise and delivery track record
Strong leadership team with global industry expertise and delivery track record… Neeraj Sharma (Chief Executive Officer and Managing Director) Anurag Bhagania (Chief Financial Officer) Neeraj Sharma has over 30 years of global experience across India, South-East Asia, Latin Anurag Bhagania is a fina
Slide 17: Supported by a diverse and Independent Board
…supported by a diverse and Independent Board to build on the group’s strong corporate governance legacy Arun Kumar Debarati Sen Arun Kumar is a first-generation entrepreneur and known for his ability to identify great opportunities in Debarati Sen is Group President at HMTX Industries, a global lea
Slide 18: Get in touch with us
Get in touch with us REGISTERED AND CORPORATE OFFICE INVESTOR RELATIONS OneSource Specialty Pharma Ltd Investor-relations@onesourcecdmo.com Investor-relations@onesourcecdmo.com Registered Office: Unit No. 902, Cyber One, Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai, Sanpada, Thane, Maharashtra, I
OneSource Specialty Pharma — Q1 FY2026 Earnings Presentation on 6ix